NEWS IN BRIEF
This article was originally published in The Silver Sheet
Executive Summary
New SOP on FDA guidance development
You may also be interested in...
Medtronic: Bulk ICD Orders Down, But GPO Decision Not To Blame
Medtronic says it received noticeably fewer bulk orders from hospitals for cardiac rhythm management devices in its most recent fiscal quarter, but insists the outcome was not related to its decision to cancel certain large group purchasing organization contracts.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.